

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II

## SAFETY DATA SHEET

### **Tetramethyl Rhodamine (TRITC)-Conjugated Antibodies and Streptavidin, freeze-dried with preservative**

#### **SECTION 1: Identification of the substance/mixture and of the company/undertaking**

##### **1.1 Product identifier**

**Product name:** Tetramethyl Rhodamine (TRITC)-Conjugated Antibodies and Streptavidin, freeze-dried with preservative

**Product code:**

016-020-084	115-026-003	115-026-003	305-026-045	305-026-045	315-026-003	709-026-098
112-026-003	115-026-006	115-026-006	305-026-046	305-026-046	315-026-045	709-026-149
112-026-062	115-026-008	115-026-008	305-026-047	305-026-047	315-026-046	711-025-152
112-026-068	115-026-020	115-026-020	307-025-003	307-025-003	315-026-047	711-026-152
112-026-071	115-026-062	115-026-062	307-026-003	307-026-003	323-025-021	712-025-150
112-026-072	115-026-068	115-026-068	308-025-003	308-025-003	415-025-166	712-025-153
112-026-075	115-026-071	115-026-071	309-025-003	309-025-003	515-025-003	712-026-150
114-025-003	115-026-072	115-026-072	309-025-006	309-025-006	515-025-062	712-026-153
115-025-003	115-026-075	115-026-075	309-025-008	309-025-008	515-025-071	713-025-003
115-025-006	123-025-021	123-025-021	309-025-011	309-025-011	515-025-072	713-025-147
115-025-008	127-025-099	127-025-099	309-025-015	309-025-015	703-025-155	713-026-147
115-025-020	127-025-160	127-025-160	309-025-064	309-025-064	703-026-155	715-025-020
115-025-044	200-022-037	200-022-037	309-025-082	309-025-082	705-025-003	715-025-140
115-025-062	200-022-156	200-022-156	309-025-095	309-025-095	705-025-147	715-025-150
115-025-068	200-022-211	200-022-211	309-025-107	309-025-107	705-026-147	715-025-151
115-025-071	205-025-108	205-025-108	309-026-003	309-026-003	706-025-148	715-026-020
115-025-072	209-025-082	209-025-082	309-026-008	309-026-008	706-026-148	715-026-150
115-025-075	209-025-088	209-025-088	309-026-043	309-026-043	709-025-073	715-026-151
115-025-146	209-025-097	209-025-097	312-025-003	312-025-003	709-025-098	805-025-180
115-025-164	209-025-098	209-025-098	312-025-020	312-025-020	709-025-149	
115-025-166	211-025-109	211-025-109	312-025-044	312-025-044	709-026-073	

**SDS #:** 5EU

##### **Product description:**

016-020-084	Rhodamine (TRITC)-Streptavidin
112-026-003	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Rat IgG (H+L)
112-026-062	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
112-026-068	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Rat IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)
112-026-071	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Rat IgG, Fcγ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
112-026-072	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Rat IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
112-026-075	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Rat IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)
114-025-003	Rhodamine (TRITC)-AffiniPure Goat Anti-Swine IgG (H+L)
115-025-003	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG (H+L)
115-025-006	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG, F(ab') <sub>2</sub> Fragment Specific
115-025-008	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG, Fcγ Fragment Specific
115-025-020	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgM, μ Chain Specific
115-025-044	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG + IgM (H+L)
115-025-062	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
115-025-068	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)
115-025-071	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG, Fcγ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
115-025-072	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
115-025-075	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)
115-025-146	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs,Rb,Sw Sr Prot)
115-025-164	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG (subclasses 1+2a+2b+3) Fcγ Fragment Specific (min X Hu,Bov,Rb Sr Prot)
115-025-166	Rhodamine (TRITC)-AffiniPure Goat Anti-Mouse IgG (H+L) (min X Rat,Hu,Bov,Hrs,Rb Sr Prot)
115-026-003	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgG (H+L)
115-026-006	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgG, F(ab') <sub>2</sub> Fragment Specific
115-026-008	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgG, Fcγ Fragment Specific
115-026-020	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgM, μ Chain Specific
115-026-062	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
115-026-068	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgG + IgM (H+L) (min X Hu,Bov,Hrs Sr Prot)
115-026-071	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgG, Fcγ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
115-026-072	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
115-026-075	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Goat Anti-Mouse IgM, μ Chain Specific (min X Hu,Bov,Hrs Sr Prot)
123-025-021	Rhodamine (TRITC)-AffiniPure Goat Anti-Horseradish Peroxidase
127-025-099	Rhodamine (TRITC)-AffiniPure Goat Anti-Armenian Hamster IgG (H+L) (min X Bov Sr Prot)
127-025-160	Rhodamine (TRITC)-AffiniPure Goat Anti-Armenian Hamster IgG (H+L) (min X Bov,Hu,Ms,Rb,Rat Sr Prot)
200-022-037	Rhodamine (TRITC)-IgG Fraction Monoclonal Mouse Anti-Fluorescein (FITC)
200-022-156	Rhodamine (TRITC)-IgG Fraction Monoclonal Mouse Anti-Digoxin
200-022-211	Rhodamine (TRITC)-IgG Fraction Monoclonal Mouse Anti-Biotin
205-025-108	Rhodamine (TRITC)-AffiniPure Mouse Anti-Goat IgG (H+L) (min X Ms,Hu,Rb Sr Prot)
209-025-082	Rhodamine (TRITC)-AffiniPure Mouse Anti-Human IgG (H+L) (min X Ms Sr Prot)
209-025-088	Rhodamine (TRITC)-AffiniPure Mouse Anti-Human IgG (H+L) (min X Bov,Hrs,Ms Sr Prot)
209-025-097	Rhodamine (TRITC)-AffiniPure Mouse Anti-Human IgG, F(ab') <sub>2</sub> Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
209-025-098	Rhodamine (TRITC)-AffiniPure Mouse Anti-Human IgG, Fcγ Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
211-025-109	Rhodamine (TRITC)-AffiniPure Mouse Anti-Rabbit IgG (H+L) (min X Hu,Gt,Ms,Shp Sr Prot)
212-025-082	Rhodamine (TRITC)-AffiniPure Mouse Anti-Rat IgG (H+L) (min X Ms Sr Prot)
212-025-104	Rhodamine (TRITC)-AffiniPure Mouse Anti-Rat IgG, Fcγ Fragment Specific (min X Hu,Bov,Hrs,Ms Sr Prot)
212-025-106	Rhodamine (TRITC)-AffiniPure Mouse Anti-Rat IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs,Ms Sr Prot)

212-025-168	Rhodamine (TRITC)-AffiniPure Mouse Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs,Ms,Gt,Rb Sr Prot)
212-026-168	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Mouse Anti-Rat IgG (H+L) (min X Hu,Bov,Hrs,Ms,Gt,Rb Sr Prot)
301-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Bovine IgG (H+L)
303-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Chicken IgY (IgG) (H+L)
303-025-006	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Chicken IgY (IgG), F(ab') <sub>2</sub> Fragment Specific
303-025-008	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Chicken IgY (IgG), Fc Fragment Specific
303-026-003	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Chicken IgY (IgG) (H+L)
304-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Dog IgG (H+L)
304-025-008	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Dog IgG, Fc Fragment Specific
305-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Goat IgG (H+L)
305-025-006	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Goat IgG, F(ab') <sub>2</sub> Fragment Specific
305-025-008	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Goat IgG, Fc Fragment Specific
305-025-045	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Goat IgG (H+L) (min X Hu Sr Prot)
305-025-046	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Goat IgG, Fc Fragment Specific (min X Hu Sr Prot)
305-025-047	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Goat IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu Sr Prot)
305-026-003	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Goat IgG (H+L)
305-026-006	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Goat IgG, F(ab') <sub>2</sub> Fragment Specific
305-026-008	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Goat IgG, Fc Fragment Specific
305-026-045	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Goat IgG (H+L) (min X Hu Sr Prot)
305-026-046	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Goat IgG, Fc Fragment Specific (min X Hu Sr Prot)
305-026-047	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Goat IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu Sr Prot)
307-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Syrian Hamster IgG (H+L)
307-026-003	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Syrian Hamster IgG (H+L)
308-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Horse IgG (H+L)
309-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human IgG (H+L)
309-025-006	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human IgG, F(ab') <sub>2</sub> Fragment Specific
309-025-008	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human IgG, Fcy Fragment Specific
309-025-011	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human Serum IgA, α Chain Specific
309-025-015	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human Lactoferrin
309-025-064	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human IgA+IgG+IgM (H+L)
309-025-082	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human IgG (H+L) (min X Ms Sr Prot)
309-025-095	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human IgM, Fc5μ Fragment Specific (min X Ms Sr Prot)
309-025-107	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Human IgG + IgM (H+L) (min X Ms Sr Prot)
309-026-003	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Human IgG (H+L)
309-026-008	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Human IgG, Fcy Fragment Specific
309-026-043	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Human IgM, Fc5μ Fragment Specific
312-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Rat IgG (H+L)
312-025-020	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Rat IgM, μ Chain Specific
312-025-044	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Rat IgG + IgM (H+L)
312-025-045	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Rat IgG (H+L) (min X Hu Sr Prot)
312-025-046	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Rat IgG, Fcy Fragment Specific (min X Hu Sr Prot)
312-025-047	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Rat IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu Sr Prot)
312-025-048	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Rat IgG + IgM (H+L) (min X Hu Sr Prot)
312-025-049	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Rat IgM, μ Chain Specific (min X Hu Sr Prot)
312-026-045	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Rat IgG (H+L) (min X Hu Sr Prot)
313-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Sheep IgG (H+L)
313-025-045	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Sheep IgG (H+L) (min X Hu Sr Prot)
313-025-046	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Sheep IgG, Fc Fragment Specific (min X Hu Sr Prot)
313-025-047	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Sheep IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu Sr Prot)
313-026-003	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Sheep IgG (H+L)
315-025-003	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgG (H+L)
315-025-006	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgG, F(ab') <sub>2</sub> Fragment Specific
315-025-008	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgG, Fcy Fragment Specific
315-025-020	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgM, μ Chain Specific
315-025-044	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgG + IgM (H+L)
315-025-045	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgG (H+L) (min X Hu Sr Prot)
315-025-046	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgG, Fcy Fragment Specific (min X Hu Sr Prot)
315-025-047	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu Sr Prot)
315-025-048	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgG + IgM (H+L) (min X Hu Sr Prot)
315-025-049	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Mouse IgM, μ Chain Specific (min X Hu Sr Prot)
315-026-003	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Mouse IgG (H+L)
315-026-045	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Mouse IgG (H+L) (min X Hu Sr Prot)
315-026-046	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Mouse IgG, Fcy Fragment Specific (min X Hu Sr Prot)
315-026-047	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Rabbit Anti-Mouse IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu Sr Prot)
323-025-021	Rhodamine (TRITC)-AffiniPure Rabbit Anti-Horseradish Peroxidase
415-025-166	Rhodamine (TRITC)-AffiniPure Rat Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs,Rat,Rb Sr Prot)
515-025-003	Rhodamine (TRITC)-AffiniPure Sheep Anti-Mouse IgG (H+L)
515-025-062	Rhodamine (TRITC)-AffiniPure Sheep Anti-Mouse IgG (H+L) (min X Hu,Bov,Hrs Sr Prot)
515-025-071	Rhodamine (TRITC)-AffiniPure Sheep Anti-Mouse IgG, Fcy Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
515-025-072	Rhodamine (TRITC)-AffiniPure Sheep Anti-Mouse IgG, F(ab') <sub>2</sub> Fragment Specific (min X Hu,Bov,Hrs Sr Prot)
703-025-155	Rhodamine (TRITC)-AffiniPure Donkey Anti-Chicken IgY (IgG) (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
703-026-155	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Chicken IgY (IgG) (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
705-025-003	Rhodamine (TRITC)-AffiniPure Donkey Anti-Goat IgG (H+L)
705-025-147	Rhodamine (TRITC)-AffiniPure Donkey Anti-Goat IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
705-026-147	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Goat IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
706-025-148	Rhodamine (TRITC)-AffiniPure Donkey Anti-Guinea Pig IgG (H+L) (min X Bov,Ck,Gt,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
706-026-148	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Guinea Pig IgG (H+L) (min X Bov,Ck,Gt,Sy Hms,Hrs,Hu,Ms,Rb,Rat,Shp Sr Prot)
709-025-073	Rhodamine (TRITC)-AffiniPure Donkey Anti-Human IgM, Fc5μ Fragment Specific (min X Bov,Hrs Sr Prot)
709-025-098	Rhodamine (TRITC)-AffiniPure Donkey Anti-Human IgG, Fcy Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
709-025-149	Rhodamine (TRITC)-AffiniPure Donkey Anti-Human IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Ms,Rb,Rat,Shp Sr Prot)
709-026-073	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Human IgM, Fc5μ Fragment Specific (min X Bov,Hrs Sr Prot)
709-026-098	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Human IgG, Fcy Fragment Specific (min X Bov,Hrs,Ms Sr Prot)
709-026-149	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Human IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Ms,Rb,Rt,Shp Sr Prot)
711-025-152	Rhodamine (TRITC)-AffiniPure Donkey Anti-Rabbit IgY (IgG) (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rat,Shp Sr Prot)
711-026-152	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Rabbit IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rat,Shp Sr Prot)
712-025-150	Rhodamine (TRITC)-AffiniPure Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
712-025-153	Rhodamine (TRITC)-AffiniPure Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Shp Sr Prot)
712-026-150	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
712-026-153	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Rat IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Ms,Rb,Shp Sr Prot)
713-025-003	Rhodamine (TRITC)-AffiniPure Donkey Anti-Sheep IgG (H+L)
713-025-147	Rhodamine (TRITC)-AffiniPure Donkey Anti-Sheep IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
713-026-147	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Sheep IgG (H+L) (min X Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)
715-025-020	Rhodamine (TRITC)-AffiniPure Donkey Anti-Mouse IgM, μ Chain Specific
715-025-140	Rhodamine (TRITC)-AffiniPure Donkey Anti-Mouse IgM, μ Chain Specific (min X Hu,Bov,Hrs,Rat Sr Prot)
715-025-150	Rhodamine (TRITC)-AffiniPure Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
715-025-151	Rhodamine (TRITC)-AffiniPure Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Rat,Shp Sr Prot)
715-026-020	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Mouse IgM, μ Chain Specific
715-026-150	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Shp Sr Prot)
715-026-151	Rhodamine (TRITC)-AffiniPure F(ab') <sub>2</sub> Fragment Donkey Anti-Mouse IgG (H+L) (min X Bov,Ck,Gt,GP,Sy Hms,Hrs,Hu,Rb,Rat,Shp Sr Prot)
805-025-180	Rhodamine (TRITC)-AffiniPure Bovine Anti-Goat IgG (H+L) (min X Bov,Ck,GP,Sy Hms,Hrs,Hu,Ms,Rb,Rat Sr Prot)

**Product type:** Freeze-dried powder

Other means  
of identification: None

## 1.2 Revelant identified uses of the substance or mixtureidentifier

For *in vitro* research use only. Not for diagnostic or therapeutic use. This is not a medical device. Contact suppliers for specific applications.

## 1.3 Details of the supplier of the safety data sheet

### European Contact

Jackson ImmunoResearch Europe LTD  
Unit 7, Acorn Business Centre  
Oaks Drive, Newmarket,  
Suffolk, CB8 7SY, UK  
T: +44 (0) 1638 782616  
F: +44 (0) 1638 668462  
cuserv@jireurope.com  
www.jireurope.com

### Manufacturer

Jackson ImmunoResearch Laboratories, Inc.  
872 West Baltimore Pike  
West Grove, PA 19390  
T: 800-367-5296, 610-869-4024  
F: 610-869-0171  
cuserv@jacksonimmuno.com  
tech@jacksonimmuno.com  
www.jacksonimmuno.com

E-mail address of the person responsible for this SDS: tech@jacksonimmuno.com

## 1.4 Emergency telephone number

### Emergency Contact

Telephone number: CHEMTREC:  
800-424-9300  
OUTSIDE USA:  
703-527-3887

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

Product definition: Mixture

#### Classification according to Directive 1999/45/E [DPD] Europe

This product is not classified as dangerous after rehydration according to directive 1999/45/EC and its amendments.

Classification: Not classified.

See Section 16 for the full text of the R phrases or H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

Hazard symbol or symbols: N/A

Indication of danger: N/A

Risk phrases: After rehydration, this product is not classified according to EU legislation.

Safety phrases: Not applicable.

Hazardous ingredients: The only danger of this product is associated with sodium azide which is present in a very small amount. After rehydration, sodium azide is below the threshold level of 1% for a toxic chemical.

Supplemental label elements: Not applicable.

#### Special packaging requirements

Containers to be fitted with child-resistant fastenings: Not applicable.

Tactile warning of danger: Not applicable.

### 2.3 Other hazards

Other hazards which do not result in classification: Not applicable

## SECTION 3: Composition/information on ingredients

Substance/mixture: Mixture

Chemical Name	CAS#	EC #	% (w/w)
Sodium Azide	26628-22-8	247-852-1	2 [0.05%(w/v)after rehydration]
Sodium Phosphate	7558-79-4	231-448-7	4
Tetramethyl rhodamine-conjugated antibody	N/A	N/A	5
Sodium Chloride	7647-14-5	231-598-3	44
Bovine Serum Albumin	N/A	N/A	45

This mixture is not considered to be hazardous after rehydration for use.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

**Eye contact:** If this product enters the eyes, flush the eyes with gently running water for at least 15 minutes. If inflammation occurs, get medical attention.

**Inhalation:** Vapors of these products are likely to be only water vapors, so no adverse health effects are expected if vapors are inhaled. If irritation occurs, get medical attention.

**Skin contact:** Basic hygiene should prevent any problems. If contact with these products leads to reddening, inflammation, or irritation, flush exposed area with running water and get medical attention.

**Ingestion:** Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. Give small quantities of water to drink. Do not induce vomiting unless directed by medical personnel. These products are for *in vitro* research use only, not for household, diagnostic, or therapeutic use. They are not medical devices. If these products are accidentally swallowed, no adverse health effects are expected. However, no special precautions are taken to remove or detect the possible presence of endotoxin or pyrogens. If fever or adverse effects are experienced, get medical attention.

**Protection of first-aiders:** No action shall be taken involving any personal risk or without suitable training.

#### 4.2 Most important symptoms and effects, both acute and delayed

##### Potential acute health effects

**Eye contact:** No known significant effects or critical hazards.

**Inhalation:** No known significant effects or critical hazards.

**Skin contact:** No known significant effects or critical hazards.

**Ingestion:** No known significant effects or critical hazards.

##### Over-exposure signs/symptoms

**Eye contact:** No specific data.

**Inhalation:** No specific data.

**Skin Contact:** No specific data.

**Ingestion:** No specific data.

#### 4.3 Indication of any immediate medical attention and special treatment needed

**Notes to physician:** Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

**Specific treatments:** No specific treatment.

## SECTION 5: Fire-fighting measures

5.1

### Extinguishing media

**Suitable extinguishing media:** Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing media:** None known.

#### 5.2 Special hazards arising from the substance or mixture

**Hazards from the substance or mixture:** In a fire or if heated, a pressure increase will occur and the container may burst.

**Hazardous combustion products:** Decomposition products may include oxides of carbon, nitrogen, and phosphorus in very small quantities.

#### 5.3 Advice for fire fighters

**Special precautions for fire fighters:** Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

**Special protective equipment for fire fighters:** Fire fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-face piece operated in positive pressure mode. Clothing for fire fighters (including helmets, protective boots, and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

## SECTION 6. Accidental release measures

6.1 Personal

### precautions, protective equipment, and emergency procedures

**For non-emergency personnel:** No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas.

Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

**For emergency responders:**

**6.2 Environmental precautions:** Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil, or air).

#### 6.3 Methods and materials for containment and cleaning up

**Small spill:** Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water soluble. Alternatively, or if water insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

**Large spill:** Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements, or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material, e.g. sand, earth, vermiculite, or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via licensed waste disposal contractor.

**6.4 Reference to other sections:** See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

## SECTION 7: Handling and storage

The information

in this section contains generic advice and guidelines. The list of Identified Uses in Section 1 should be consulted for any available use specific information provided in the Exposure Scenario(s).

### 7.1 Precautions for safe handling

**Protective measures:** Put on appropriate protective equipment (see Section 8).

**Advice on general occupational hygiene:** Eating, drinking, and smoking should be prohibited in areas where material is handled, stored, and processed. Workers should wash hands and face before eating, drinking, and smoking. Remove contaminated clothing and protective equipment entering eating areas. See also Section 8 for additional information on hygiene measures.

**7.2 Conditions for safe storage, including any incompatibilities:** Store at 2-8 ° C under sterile conditions. Store in original container away from incompatible materials (see Section 10) and food and drink. Keep container tightly sealed until ready to use. Prepare working dilution fresh each day. Remove aliquots for dilution and reseal container under sterile conditions. Do not store in unlabeled container. Use appropriate containment to avoid environmental contamination. Consult Product Specification sheets for additional storage information.

### 7.3 Specific end uses

**Recommendations:** Not available.  
**Industrial sector specific solutions:** Not available.

## SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 8.1 Control parameters

#### Occupational exposure limits

**Europe:** No exposure limit value known.

**Recommended monitoring procedures:** If this product contains ingredients with exposure limits, personal, workplace atmosphere, or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to European Standard EN689 for methods for the assessment of exposure by inhalation to chemical agents and national guidance documents for methods for the determination of hazardous substances.

#### Derived effect levels

No DELs available

#### Predicted effect concentrations

No PECs available

### 8.2 Exposure controls

**Appropriate engineering controls:** No special ventilation requirements. Good general ventilation should be sufficient to control worker exposure to airborne contaminants. If this product contains ingredients with exposure limits, use process enclosures, local exhaust ventilation, or other engineering controls to keep worker exposure below any recommended or statutory limits.

#### Individual protection measures

**Hygiene measures:** Wash hands, forearms, and face thoroughly after handling chemical products, before eating, smoking, and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure the eyewash station and safety showers are close to the workstation location.

**Eye/face protection:** Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, or dusts.

#### Skin protection

**Hand protection:** Chemical resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

**Body protection:** Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Other skin protection:** Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection:** Use a properly-fitted, air-purifying, or air-fed respirator complying with an approved standard if a risk assessment indicates this is a necessity. Respirator selection must be on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.

**Environmental exposure controls:** Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters, or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

## SECTION 9: Physical and chemical properties

### 9.1 Information

#### on basic physical and chemical properties

##### Appearance

**Physical state:** Liquid

**Color:** Colorless, as water

**Odor:** Odorless, as water

**Odor threshold:** Not available

**pH:** 7.6

**Melting point/freezing point:** Not available

**Initial boiling point and boiling range:** Not available

**Flash point:** Not available

**Evaporation rate:** Not available

**Flammability:** Not available

**Burning time:** Not available

**Burning rate:** Not available

**Upper/lower flammability or explosive limits:** Not available

**Vapor pressure:** Not available

**Vapor density:** Not available

**Relative density:** Not available

**Solubility(ies):** Soluble in warm and cold water

**Partition coefficient:** n-octanol/water

**Auto-ignition temperature:** Not available

**Decomposition temperature:** Not available

**Viscosity:** Not available

**Explosive properties:** Not available

**Oxidizing properties:** Not available

### 9.2 Other information

No additional information

## SECTION 10: Stability and reactivity

### 10.1 Reactivity:

No specific test data related to reactivity available for this product or its ingredients.

**10.2 Chemical stability:** The product is stable.

**10.3 Possibility of hazardous reactions:** Under normal conditions of storage and use, hazardous reactions will not occur.

**10.4 Conditions to avoid:** No specific data.



**10.5 Incompatible materials:** No specific data.

**10.6 Hazardous decomposition products:** Under normal conditions of storage and use, hazardous decomposition products will not be produced.

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

#### Acute toxicity

**Sodium Chloride:** Oral Rat, LD50, 3,000 mg/kg

**Sodium Phosphate:** Oral Rat, LD50, 17g/kg

**Sodium Azide:** Oral Rat, LD50, 27 mg/kg

**Antibody/Serum Protein:** Not established.

#### Irritation/Corrosion

**Conclusion/Summary:** Not available.

#### Sensitizer

**Conclusion/Summary:** Not available.

#### Mutagenicity

**Conclusion/Summary:** Not available.

#### Carcinogenicity

**Conclusion/Summary:** Not available.

#### Reproductive toxicity

**Conclusion/Summary:** Not available.

#### Teratogenicity

**Conclusion/Summary:** Not available.

**Information on the likely routes of exposure:** Routes of entry anticipated: Oral, Dermal, and Inhalation.

#### Potential acute health effects

**Inhalation:** No known significant effects or critical hazards.

**Ingestion:** No known significant effects or critical hazards.

**Skin contact:** No known significant effects or critical hazards.

**Eye contact:** No known significant effects or critical hazards.

#### Symptoms related to the physical, chemical, and toxicological characteristics

**Inhalation:** No specific data.

**Ingestion:** No specific data.

**Skin contact:** No specific data.

**Eye contact:** No specific data.

#### Delayed, immediate, and chronic effects from short and long term exposure

##### Short term exposure

**Potential immediate effects:** Not available.

**Potential delayed effects:** Not available.

##### Long term effects

**Potential immediate effects:** Not available.

**Potential delayed effects:** Not available.

#### Potential chronic health effects

**Conclusion/Summary:** Not available.

**General:** No known significant effects or critical hazards.

**Carcinogenicity:** No known significant effects or critical hazards.

**Mutagenicity:** No known significant effects or critical hazards.

**Teratogenicity:** No known significant effects or critical hazards.

**Developmental effects:** No known significant effects or critical hazards.

**Fertility effects:** No known significant effects or critical hazards.

**Other information:** Not available.

## SECTION 12: Ecological information

### 12.1 Toxicity

**Conclusion/Summary:** Not available.

### 12.2 Persistence and degradability

**Conclusion/Summary:** Not available.

### 12.3 Bioaccumulative potential

Not available.

### 12.4 Mobility in soil

**Soil/water partition coefficient:** Not available.

**Mobility:** Not available.

### 12.5 Results of PBT and vPvB assessment

**PBT:** Not applicable.

**vPvB:** Not applicable.

### 12.6 Other adverse effects:

No known significant effects or critical hazards.

## SECTION 13. Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 13.1 Waste treatment methods

#### Product

**Methods of disposal:** The generation of waste should be avoided or minimized wherever possible. Significant quantities of waste product residues should not be disposed of via the foul sewer but processed in a suitable effluent treatment plant. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Disposal of this product, solutions, and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers.

**Hazardous waste:** Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 91/689/EEC.

## Packaging

**Methods of disposal:** The generation of waste should be avoided or minimized whenever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions:** This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains, and sewers.

SECTION 14: Transport information				
	ADR/RID	ADN/ADNR	IMDG	IATA
14.1 UN number	Not available	Not available	Not available	Not available
14.2 UN proper shipping name	Not available	Not available	-	-
14.3 Transport hazard class(es)	Not available	Not available	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No	No	No	No
14.6 Special precaution for user	Not available	Not available	Not available	Not available
Additional information	-	-	-	-

**14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the and the IBC Code:** Not available.

## SECTION 15: Regulatory information

### 15.1 Safety, health, and environmental regulations/legislation specific for the substance or mixture

#### EU Regulation (EC) No. 1907/2006 (REACH)

##### Annex XIV - List of substances subject to authorization

###### Substances of very high concern

None of the components are listed.

**Annex XVII - Restrictions on the manufacture, placing on the market, and use of certain dangerous substances, mixtures, and articles:** Not applicable.

#### Other EU regulations

**Europe inventory:** Not determined.

**Black List Chemicals:** Not listed.

**Priority List Chemicals:** Not listed.

**Integrated pollution prevention and control list (IPPC) - Air:** Not listed.

**IPPC - Water:** Not listed.

#### National Regulations

**15.2 Chemical Safety Assessment:** This product contains substances for which Chemical Safety Assessments are still required.

## SECTION 16: Other information

**Abbreviations and acronyms:** ATE = Acute Toxicity Estimate

CLP = Classification, Labelling, and Packaging Regulation [Regulation (EC) No. 1272/2008]

DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard Statement

PNEC = Predicted No Effect Concentration

RRN = REACH Registration Number

#### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
----------------	---------------

#### Europe

**Full text of abbreviation H statements:** Not applicable.

**Full text of classifications [CLP/GHS]:** Not applicable.

**Full text of abbreviated R phrases:** Not applicable.

**Full text of classifications[DSD/DPD]:** Not applicable.

**Date of printing:** 10/10/2010

**Date of issue/Date of revision:** 5/9/2012

**Date of previous issue:** No previous validation.

**Version:** 1.01

#### Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

